We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Amgen, TOTAL, Marriott, PG&E and Vertex
Read MoreHide Full Article
For Immediate Release
Chicago, IL – February 21, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Amgen (AMGN - Free Report) , TOTAL S.A. , Marriott (MAR - Free Report) , PG&E (PCG - Free Report) and Vertex (VRTX - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Analyst Reports for Amgen, TOTAL and Marriott
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amgen, TOTAL S.A. and Marriott. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Amgen’s shares have gained +6% over the past one year, outperforming the Zacks Biomedical and Genetics industry, which has declined -1.9% over the same period. Amgen had a rather poor quarter as it missed expectations for both earnings and sales and also issued lower-than-expected sales guidance for 2018.
The Zacks analyst likes Amgen’s newer drugs – Prolia, Xgeva, Kyprolis – which are performing well. Amgen is also progressing with its pipeline and expects approval and launch of migraine candidate, Aimovig this year. However, Amgen has some challenges in store, given slowdown in sales of mature drugs like Enbrel, Aranesp and Neulasta, which are facing an array of branded and generic competitors. Volume growth of new drugs may not be enough to offset the lost sales due to the decline in mature brands.
While Neupogen is already facing U.S. biosimilar competition, Neulasta, Epogen and Sensipar could start facing the same this year. Meanwhile, uptake of key new drug Repatha has been slow due to payer restrictions.
Shares of TOTAL S.A. have gained +10% over the last one year, outperforming the Zacks Integrated International Oil industry which has increased +6.8% over the same period. Fourth-quarter earnings of the company were better than expected due to higher oil production and improvement in commodity prices.
Going forward, the company will benefit further from upstream startups and cost management initiatives. It continues to gain from strategic acquisitions and asset divestures, which will further strengthen the portfolio. The company is utilizing its strong cash flow generating capacity to strengthen its balance sheet, pay dividend and buy back shares.
However, operations in some politically troubled regions and increasing competition could impact the company’s profitability. Due to its global presence, it is also exposed to risks associated with doing business abroad.
Buy-rated Marriott’s shares have outperformed the Zacks Hotels industry over the last one year. (the stock is up +57.4% vs. +39.1% gain for the industry). Marriott’s fourth-quarter 2017 adjusted earnings beat expectations and rose 31.8% year over year.
The company is poised to grow on the back of the Starwood acquisition, arresting brand position, an increased demand for travel and significant international exposure. With this acquisition, Marriott became the world's largest hotel company. In fact, this buyout is likely to result in a bigger brand with increased scale and a robust development pipeline in the long run.
The Zacks analyst likes Marriott’s rising North-American business, sizeable international exposure and attractive brand-position. Yet, lingering political uncertainties in key international markets and currency headwinds might continue to limit revenue growth. Moreover, integration risks linked to Starwood purchase is an added concern.
Other noteworthy reports we are featuring today include PG&E and Vertex.
Can Hackers Put Money INTO Your Portfolio?
Earlier this month, credit bureau Equifax announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others.
Zacks has just released Cybersecurity! An Investor’s Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performancefor information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Amgen, TOTAL, Marriott, PG&E and Vertex
For Immediate Release
Chicago, IL – February 21, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Amgen (AMGN - Free Report) , TOTAL S.A. , Marriott (MAR - Free Report) , PG&E (PCG - Free Report) and Vertex (VRTX - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Analyst Reports for Amgen, TOTAL and Marriott
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amgen, TOTAL S.A. and Marriott. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Amgen’s shares have gained +6% over the past one year, outperforming the Zacks Biomedical and Genetics industry, which has declined -1.9% over the same period. Amgen had a rather poor quarter as it missed expectations for both earnings and sales and also issued lower-than-expected sales guidance for 2018.
The Zacks analyst likes Amgen’s newer drugs – Prolia, Xgeva, Kyprolis – which are performing well. Amgen is also progressing with its pipeline and expects approval and launch of migraine candidate, Aimovig this year. However, Amgen has some challenges in store, given slowdown in sales of mature drugs like Enbrel, Aranesp and Neulasta, which are facing an array of branded and generic competitors. Volume growth of new drugs may not be enough to offset the lost sales due to the decline in mature brands.
While Neupogen is already facing U.S. biosimilar competition, Neulasta, Epogen and Sensipar could start facing the same this year. Meanwhile, uptake of key new drug Repatha has been slow due to payer restrictions.
Shares of TOTAL S.A. have gained +10% over the last one year, outperforming the Zacks Integrated International Oil industry which has increased +6.8% over the same period. Fourth-quarter earnings of the company were better than expected due to higher oil production and improvement in commodity prices.
Going forward, the company will benefit further from upstream startups and cost management initiatives. It continues to gain from strategic acquisitions and asset divestures, which will further strengthen the portfolio. The company is utilizing its strong cash flow generating capacity to strengthen its balance sheet, pay dividend and buy back shares.
However, operations in some politically troubled regions and increasing competition could impact the company’s profitability. Due to its global presence, it is also exposed to risks associated with doing business abroad.
Buy-rated Marriott’s shares have outperformed the Zacks Hotels industry over the last one year. (the stock is up +57.4% vs. +39.1% gain for the industry). Marriott’s fourth-quarter 2017 adjusted earnings beat expectations and rose 31.8% year over year.
The company is poised to grow on the back of the Starwood acquisition, arresting brand position, an increased demand for travel and significant international exposure. With this acquisition, Marriott became the world's largest hotel company. In fact, this buyout is likely to result in a bigger brand with increased scale and a robust development pipeline in the long run.
The Zacks analyst likes Marriott’s rising North-American business, sizeable international exposure and attractive brand-position. Yet, lingering political uncertainties in key international markets and currency headwinds might continue to limit revenue growth. Moreover, integration risks linked to Starwood purchase is an added concern.
Other noteworthy reports we are featuring today include PG&E and Vertex.
Can Hackers Put Money INTO Your Portfolio?
Earlier this month, credit bureau Equifax announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others.
Zacks has just released Cybersecurity! An Investor’s Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.
Download the new report now>>
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performancefor information about the performance numbers displayed in this press release.